Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease
Ladan Zand, Vicente E Torres, Timothy S Larson, Bernard F King, Sanjeev Sethi, Eric J Bergstralh, Andrea Angioi, Fernando C Fervenza, Ladan Zand, Vicente E Torres, Timothy S Larson, Bernard F King, Sanjeev Sethi, Eric J Bergstralh, Andrea Angioi, Fernando C Fervenza
Abstract
Background: To determine the effect of statins on renal hemodynamics in normal volunteers and those with autosomal dominant polycystic kidney disease either with mild or moderate renal dysfunction.
Methods: Thirty-two study subjects were enrolled in this study: 11 normal volunteers, 11 study subjects with autosomal dominant polycystic kidney disease (ADPKD) and mild kidney disease and 10 study subjects with ADPKD and moderate kidney disease. Subjects in each group received simvastatin 40 mg once daily for a period of 4 weeks. Renal blood flow was measured based on para-amino-hippurate (PAH) clearance and with the use of a magnetic resonance (MR) scanner at the beginning and following 4 weeks of therapy with statins.
Results: At the end of the study, except for the lipid profile, which was significantly lower in all groups, other laboratory results showed no change. Four weeks of therapy with simvastatin resulted in no change in serum creatinine, 24-h urinary protein, sodium, iothalamate clearance, PAH clearance or renal blood flow as measured by MRI or based on PAH clearance.
Conclusions: Four weeks of therapy with simvastatin did not change renal blood flow in the study subjects with ADPKD with mild-to-moderate renal dysfunction or in healthy volunteers.
Clinical trial registration number: NCT02511418.
Keywords: ADPKD; HMG-CoA reductase inhibitor; renal blood flow; statins.
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Source: PubMed